1. Introduction {#sec1}
===============

Syphilis is a sexually transmitted chronic disease caused by the spirochete *Treponema pallidum,* which can be spread via mother-to-child transmission (congenital syphilis) or acquired in adulthood (acquired syphilis). It was estimated that there were 5.6 million new cases of syphilis worldwide in 2012, with a global prevalence of 0.5% among people aged 15--49 years \[[@B1]\]. According to a 22-year survey of incident uveitis cases, the actual frequency of syphilitic uveitis was \<1%, but the incidence has risen markedly \[[@B2]\].

Syphilitic uveitis is an infectious type of uveitis that should be included in the differential diagnosis of any form of ocular inflammation. Syphilitic uveitis can occur at any stage of acquired syphilis. It can result in visual loss if it is unrecognized or if it is mistreated as a noninfectious ocular inflammation. It can affect various parts of the eye and may present as anterior uveitis, posterior uveitis, panuveitis, retinitis, papillitis, and even scleritis, making it a "great masquerader" \[[@B3]\]. Misdiagnosis could lead to unnecessary or even harmful therapies, resulting in deterioration of uveitis and possibly even the patient\'s general health. However, syphilitic uveitis is curable with early aggressive use of antibacterial agents, making its prompt diagnosis a clinical necessity.

To manage syphilis, European (International Union against Sexually Transmitted Infections) \[[@B4]\] and United States (Centers for Disease Control and Prevention (CDC)) \[[@B5]\] guidelines recommend standard use of intravenous benzyl penicillin at a dose of 12--24 million units per day, with 3-4 million units given every 4 h, for 10--21 days. The recent World Health Organization Sexually Transmitted Infection (STI) guidelines recommend benzathine penicillin G administered intramuscularly at a dose of 2.4 million units once weekly for three consecutive weeks to treat late syphilis (including ocular syphilis) \[[@B6]\].

Because immunological reactions are also believed to be involved in the pathogenesis of late syphilis \[[@B7]\], it seems reasonable to administer corticosteroids or other immunosuppressants in combination with standard antibacterial regimens to treat syphilitic uveitis. However, there is limited evidence regarding their efficacy of corticosteroids or other immunosuppressants for treating syphilitic uveitis.

Syphilis and human immunodeficiency virus (HIV) coinfection is common \[[@B8]\], and the prevalence of ocular syphilis in HIV-positive patients was very high, 9%, in an earlier study \[[@B9]\]. The immune status of these patients might be complicated, resulting in alterations of the clinical or laboratory manifestations of syphilis, increased risk of syphilitic complications, and diminished responses to antibacterial agents. The infection was also common in posterior regions of the eye in patients coinfected with HIV in several studies \[[@B9], [@B10]\]. Considering these issues, the outcomes of antibacterial agents in patients with syphilitic uveitis and HIV are of particular interest.

The objectives of this systematic review and meta-analysis were to summarize the clinical and laboratory features of patients with syphilitic uveitis and to assess the efficacy of antibacterial agents administered alone or in combination with other agents.

2. Methods {#sec2}
==========

2.1. Electronic Database Searches {#sec2.1}
---------------------------------

PubMed was searched in October 2016 using the terms "ocular \[All Fields\]," "intraocular \[All Fields\]," or "uveitis \[All Fields\]," which were then matched with "syphilis \[All Fields\]" or "syphilitic \[All Fields\]." Articles published between January 1990 and October 2016 were retrieved, and the reference lists of the retrieved articles were manually checked for relevant articles. We also searched the Web of Science for articles citing the articles retrieved from PubMed, and the additional articles were assessed for possible inclusion. Observational studies (including retrospective and prospective cohort studies, case-control studies, cross-sectional studies, case series, and clinical studies) that reported the clinical features of syphilitic uveitis and their treatment outcome were included. The exclusion criteria were as follows: studies that did not report the full syphilitic uveitis spectrum or did not focus on the clinical features of syphilitic uveitis; studies with \<10 patients; articles published before 1990; and non-English-language studies.

2.2. Data Collection and Analysis {#sec2.2}
---------------------------------

Two independent authors (TZ and YZ) conducted the electronic and manual searches using the predetermined inclusion and exclusion criteria, and the full text of all potentially eligible studies were assessed. Any differences in study selection between the two authors were referred to a third author (GZX) and were resolved by discussion. The data were extracted from all articles by one author (TZ) and were verified by a second author (YZ). Data were collected using pre-prepared forms covering study design, patient demographics, clinical presentation, diagnosis, interventions, treatment outcomes, and factors associated with treatment outcomes.

2.3. Assessment of Risk of Bias {#sec2.3}
-------------------------------

Two authors (TZ and YZ) independently assessed the risk of bias using the Newcastle-Ottawa Quality Assessment Scale (NOS). The NOS comprises three domains: selection representativeness (four items), comparability (two items), and ascertainment of either the exposure or outcome (three items). Each item was given one star if addressed. Scores of \>6 stars, 6 stars, and \<6 stars were considered to represent low risk of bias, medium risk of bias, and high risk of bias, respectively. Any discrepancy in the assessment of bias was resolved by discussion.

2.4. Data Synthesis {#sec2.4}
-------------------

The meta-analysis was performed in accordance with PRISMA guidelines \[[@B11]\]. The pooled success rate was defined as the percentage of eyes with improved or maintained final visual acuity after treatment. The pooled success rates with 95% confidence intervals (CI) were compared between treatment modalities using a random-effects model (DerSimonian-Laird method) or a fixed-effects model (Mantel-Haenszel method). A *P* value of \<0.05 was used to indicate statistical significance. Cochran *Q* and *I*^2^ tests were also performed to investigate study heterogeneity \[[@B12]\]. An *I*^2^ statistic of \<50% was regarded as low heterogeneity and an *I*^2^ statistic of \>75% was regarded as substantial heterogeneity. Forest plots were used to display the effects of different treatments. Funnel plots with Egger\'s and Begg\'s regression were also drawn to detect possible publication bias \[[@B13]\]. Subgroup analyses were also done to identify the correlation of the efficacy of antibacterial agents alone with relevant study characteristics (year of publication, number of involved eyes, HIV coinfection status, follow-up duration, and the geographical location of patients). R software (version 3.3.1) with the meta package was used for the meta-analyses.

3. Results {#sec3}
==========

3.1. Studies Analyzed {#sec3.1}
---------------------

A total of 769 articles were initially retrieved from PubMed ([Figure 1](#fig1){ref-type="fig"}), of which 32 were considered eligible after full-text review and were included in our analysis \[[@B14]--[@B45]\]. Most studies (31/32) were retrospective; only one was a prospective study \[[@B26]\]. Nine studies compared the clinical features and treatment outcomes between patients coinfected with HIV versus patients without HIV infection \[[@B17], [@B19], [@B22], [@B23], [@B26], [@B27], [@B33], [@B34], [@B37]\].

Using the NOS, 17 studies had a score of 5 stars, 11 studies had a score of 4 stars, 3 studies had a score of 3 stars, and 1 study had a score of 1 star.

3.2. Patient Demographics {#sec3.2}
-------------------------

The included studies comprised 670 patients, and the number of eyes in each study ranged from 11 to 139 eyes ([Table 1](#tab1){ref-type="table"}). The mean or median age of patients ranged from 37 to 58 years. Thirty studies reported a male preponderance, and the cumulative mean proportion of men was 77.5%. Nineteen studies reported sexual orientation, and the cumulative mean proportion of men who have sex with men was 50% in these studies.

3.3. Clinical Features and Diagnostic Criteria of Syphilitic Uveitis {#sec3.3}
--------------------------------------------------------------------

Sixteen studies reported the presence of systemic syphilis with a cumulative percentage of 38.5%. Bilateral involvement was more common than unilateral involvement (cumulative mean 62.1%; bilateral:unilateral ratio 1.6 : 1) in the studies that reported this information (31/32 studies) ([Table 2](#tab2){ref-type="table"}). Twenty-eight studies reported syphilitic uveitis with HIV coinfection, but the percentage of HIV coinfected patients ranged considerably from 7.7% to 100%. Seven studies reported whether HIV infection was newly diagnosed after the diagnosis of syphilis, and the percentage of affected patients ranged from 16.7% to 63.6%.

The diagnosis of syphilitic uveitis in all studies was based on clinical features (symptoms, signs, and axillary examinations) together with laboratory test confirmation. Serologic nontreponemal (rapid plasma reagin test) and treponemal specific tests (fluorescent treponemal antibody absorption test) were the most commonly used tests, being used in 17 and 21 studies, respectively. Other confirmatory laboratory tests included *Treponema pallidum* particle agglutination assays in nine studies and *Treponema pallidum* hemagglutination assays in eight studies. Twenty-nine studies also performed treponemal and reagin tests using cerebrospinal fluid (CSF) samples for the diagnosis of neurosyphilis. The venereal disease research laboratory test (VDRL) was the most common test used to detect neurosyphilis (22/29) with a cumulative positivity rate of 34.8%. CSF white blood cell (WBC) counts were reported in 9 studies, and the median WBC count ranged from 2 to 11 cells/*μ*l. CSF protein levels were reported in 8 studies, and the median protein level ranged from 42 to 464 mg/dl.

The clinical classification of uveitis was reported using the standardization of uveitis nomenclature (SUN) \[[@B46]\] in 10 studies and the standard of International Uveitis Study Group (IUSG) \[[@B47]\] in 4 studies and was not specified in 18 studies. No studies included local investigations, such as culture or polymerase chain reaction of intraocular fluid, for the diagnosis of syphilitic uveitis. Four studies reported the response to antibacterial treatment as part of the diagnosis of syphilitic uveitis.

We extrapolated further information and summarized the results according to the standardization of uveitis nomenclature, which comprises the following: anterior uveitis, intermediate uveitis, posterior uveitis, panuveitis, retinitis and retinal vasculitis, necrotizing retinitis, choroiditis, serous retinal detachment, macular edema, neuroretinitis, papillitis, and optic edema. Other phenotypes such as acute syphilitic posterior placoid choroiditis and increased intraocular pressure were also assessed. Our review revealed that the optic disc (reported in 28 studies) was the most frequently affected site (presented as papillitis, optic neuritis, or neuroretinis), and 24 studies reported syphilitic uveitis as panuveitis ([Table 3](#tab3){ref-type="table"}).

3.4. Management of Syphilitic Uveitis and Clinical Outcomes {#sec3.4}
-----------------------------------------------------------

The drugs used, regimens, route of administration, treatment duration, and follow-up duration varied considerably ([Table 4](#tab4){ref-type="table"}). Intravenous penicillin was used in 30 studies. Ceftriaxone and macrolide antibacterial agents (e.g., doxycycline or tetracycline) were used in 12 and 9 studies, respectively, in case of penicillin allergy. Additional systemic corticosteroids were used in 14 studies with a cumulative mean of 43.8% of patients. Immunosuppressants were used in 3 studies (cumulative mean of 9.4% of patients) and included methotrexate, mycophenolate mofetil, cyclophosphamide, and cyclosporine. Therefore, the patients included in this review received the following regimens: antibacterial agents alone (antibacterial monotherapy); antibacterial agents and systemic corticosteroids (double therapy); or antibacterial agents, systemic corticosteroids, and immunosuppressants (triple therapy). The mean follow-up time ranged from 2.1 to 35 months.

3.5. Antibacterial Monotherapy {#sec3.5}
------------------------------

Antibacterial agents were used as monotherapy in 286 patients in 15 studies \[[@B14], [@B17], [@B20], [@B23], [@B27], [@B30], [@B34], [@B35], [@B37], [@B39], [@B40], [@B42]--[@B45]\]. The mean age of the patients ranged from 37 to 58 years. The pooled success rate was 0.91 (95% CI 0.84--0.97) ([Figure 2(a)](#fig2){ref-type="fig"}). The heterogeneity of these studies was high (*P*~heterogeneity~ \< 0.0001; *I*^2^ statistic = 76.6%).

3.6. Antibacterial Agents and Systemic Corticosteroids {#sec3.6}
------------------------------------------------------

Antibacterial agents were used in combination with systemic corticosteroids in some patients in 11 studies involving 245 patients \[[@B15], [@B19], [@B21], [@B24], [@B25], [@B28], [@B29], [@B32], [@B33], [@B36], [@B38]\]. The mean age of the patients ranged from 38 to 57.7 years. The pooled success rate was 0.95 (95% CI 0.91--0.98) ([Figure 2(b)](#fig2){ref-type="fig"}). Study heterogeneity was low (*P*~heterogeneity~ = 0.0527; *I*^2^ statistic = 44.9%).

3.7. Antibacterial Agents, Systemic Corticosteroids, and Immunosuppressants {#sec3.7}
---------------------------------------------------------------------------

Antibacterial agents were used in combination with systemic corticosteroids and immunosuppressants in some patients in 3 studies involving 73 patients \[[@B16], [@B22], [@B31]\]. The immunosuppressants included methotrexate, mycophenolate mofetil, cyclophosphamide, and cyclosporine. Further information on how many patients received each of these individual drugs was not available. The mean age of the patients ranged from 43.75 to 45 years. The pooled success rate was 0.91 (95% CI 0.80--0.98) ([Figure 2(c)](#fig2){ref-type="fig"}). Study heterogeneity was classified as moderate (*P*~heterogeneity~ = 0.0970; *I*^2^ statistic = 57.1%).

3.8. Recurrence, Complications, and Adverse Events {#sec3.8}
--------------------------------------------------

Recurrence of ocular inflammation was assessed in the follow-up period in 13 studies involving 210 patients \[[@B14], [@B15], [@B24], [@B27], [@B28], [@B31]--[@B33], [@B36], [@B37], [@B39], [@B40], [@B43]\]. The mean follow-up time ranged from 1 to 29.4 months in these studies. The pooled estimated recurrence rate was 10.7%.

Eight studies \[[@B17], [@B21], [@B22], [@B24], [@B27], [@B28], [@B30], [@B36]\] involving 190 patients (318 eyes) reported ocular complications that included cataract (*n* = 41), ocular hypertension (*n* = 15), posterior synechiae (*n* = 15), chorioretinal scarring (*n* = 12), epiretinal membrane (*n* = 12), macular edema (*n* = 10), optic disc atrophy (*n* = 10), and retinal detachment (*n* = 8) ([Table 5](#tab5){ref-type="table"}).

Systemic adverse events (Jarisch-Herxheimer reaction) occurred in 3 patients enrolled in 3 studies involving 138 participants.

3.9. Subgroup Analysis {#sec3.9}
----------------------

The outcomes of antibacterial monotherapy were assessed in subgroups of patients divided according to the study characteristics, and the results are presented in [Table 6](#tab6){ref-type="table"}. Factors including the year of publication, the number of the eyes involved, HIV coinfection positivity, follow-up duration, and the geographical location of the patients were examined as potential sources of heterogeneity. However, we found no correlation of these study characteristics with the efficacy of antibacterial monotherapy. Nevertheless, there was substantial heterogeneity in the subgroups so *P* values for between-subgroup comparisons could not be calculated. Subgroup analyses were not possible for the other treatment regimens owing to the limited data on the drugs used.

3.10. Sensitivity and Publication Bias {#sec3.10}
--------------------------------------

In the sensitivity analysis ([Figure 2](#fig2){ref-type="fig"}), the results were similar using both fixed-effects and random-effects models. The pooled success rates using the fixed-effects and random-effects models were as follows: 0.92 (95% CI 0.88--0.94) and 0.91 (95% CI 0.84--0.97), respectively, for antibacterial monotherapy; 0.94 (95% CI 0.91--0.97) and 0.95 (95% CI 0.91--0.98), respectively, for antibacterial agents combined with systemic corticosteroids; and 0.89 (95% CI 0.83--0.95) and 0.91 (95% CI 0.80--0.98), respectively, for antibacterial agents combined with systemic corticosteroids and immunosuppressants. The funnel plots revealed no asymmetry ([Figure 3](#fig3){ref-type="fig"}). No evidence of publication bias was revealed using Begg\'s and Egger\'s regression tests, with *P* values of 0.85 for antibacterial monotherapy and 0.22 for antibacterial agents combined with systemic corticosteroids. The regression test was not done for triple therapy because of the small number of studies.

4. Discussion {#sec4}
=============

This was the first systematic review to examine the efficacies of treatments for syphilitic uveitis. Most studies focusing on the treatment of syphilitic uveitis were mainly conducted retrospectively, being cohort or case series. Thus, the strength of the results of our systematic review may be low. However, because there are very few randomized controlled trials (RCTs) in this setting, our systematic review of non-RCTs provides valuable information on the clinical features and management of syphilitic uveitis. Our review comprised 670 patients across 32 studies, which were performed in multiple clinical centers in different countries with various ethnicities. Therefore, the results should be representative of the broader population of patients with syphilitic uveitis.

The demographic characteristics of the studies included in our review are consistent with current literature on syphilitic uveitis. In particular, syphilitic uveitis is most common in men aged 37--58 years, especially in men who have sex with men. HIV coinfection was also common, supporting the screening for HIV in patients with syphilitic uveitis.

For a long time, researchers have debated whether ocular syphilis is a subtype of neurosyphilis. The data collected in our review revealed that the optic disc (reported in 28/32 studies) might be the most commonly involved in patients with syphilitic uveitis, presenting as papillitis, optic neuritis, or neuroretinis, and panuveitis was reported in 24 of 32 studies, often in the presence of retinitis or optic neuritis. These findings are consistent with the idea that ocular syphilis is a manifestation of neurosyphilis in some patients. CSF samples were tested in many patients to detect neurosyphilis. Patients with a CSF WBC count \> 10 cells/ml, protein level \> 50 mg/dl, or reactive VDRL were considered to have neurosyphilis. The cumulative VDRL positivity rate of 34.8% suggests that one in three patients with syphilitic uveitis might have neurosyphilis. However, because CSF tests with negative VDRL results do not necessarily rule out neurosyphilis \[[@B48]\], many clinicians agree that treatment of syphilitic uveitis should follow the treatment of neurosyphilis \[[@B49], [@B50]\].

In our analysis, 91% (95% CI 84 to 97) of treated patients experienced improved or maintained visual function following antibacterial monotherapy. Our analysis did not reveal any additional benefit of coadministering systemic corticosteroids or immunosupressants with antibacterial agents. In practice, clinicians often prescribe systematic corticosteroids or immunomodulary agents in combination with antibacterial agents to patients with severe ocular inflammation or chronic macular edema \[[@B51], [@B52]\]. However, there is no consensus regarding the treatment of these conditions, and a systematic review is underway to evaluate the effectiveness of treatments for uveitic macular edema \[[@B53]\]. Prospective multicenter RCTs are needed to provide definitive evidence on the use of systematic corticosteroids or immunosuppressants. A systematic review \[[@B54]\] of penicillin and non-penicillin regimens for syphilis included 11 RCTs, but the authors reported that the "evidence defining treatment for late syphilis or HIV-infected persons is limited."

Predictive factors associated with final visual acuity are of clinical interest. Our subgroup analysis did not reveal any correlation of the efficacy of antibacterial monotherapy with relevant study characteristics. In fact, only 7/32 studies reported possible factors associated with final visual acuity. Factors associated with poor visual prognosis included the time between onset of uveitis and treatment (\>12 weeks), longer duration of ocular symptoms (\>28 days), presence of macular edema or long-standing optic neuropathy, coinfection with HIV, and poor initial visual acuity. Factors associated with higher success rates included the presence of vasculitis (as detected by fundus fluorescence angiography), anterior uveitis, or neurosyphilis.

The treatment outcomes for patients with syphilitic uveitis and HIV coinfection are of considerable interest. We performed subgroup analysis to examine the efficacy of antibacterial monotherapy for syphilitic uveitis in 15 studies, which included several studies involving patients with HIV coinfection. However, stratification did not reveal any correlations of the efficacy of antibacterial monotherapy with study characteristics, including HIV coinfection status. In fact, nine studies included subgroup analyses of HIV-positive and HIV-negative patients and the factors influencing final visual acuity were investigated in these studies. Although some studies revealed a higher incidence of panuveitis in HIV-positive patients, the data for eight of the nine studies included in our analysis were inadequate to determine whether specific subtypes of uveitis were more common in HIV-positive patients. In addition, in seven of these nine studies, the authors found no differences in visual prognosis between HIV-positive and HIV-negative patients. Tucker et al. \[[@B10]\] performed a systematic analysis of 101 HIV-positive patients using data published in case series and case reports. They reported that "ocular syphilis led to the HIV diagnosis in 52% of cases, posterior uveitis was significantly more common in individuals with CD4 cell count \< 200 cells/mm^3^, and 97% of patients with visual impairment improved following intravenous penicillin or ceftriaxone." In our analysis, the mean CD4 cell count ranged from 122 to 504 cells/mm^3^, supporting the recommendations that most patients with syphilitic uveitis and HIV coinfection should be treated according to the recommendations for HIV-negative patients (e.g., as immunocompetent patients) and should be monitored closely \[[@B1]\].

There were several reviews on syphilitic uveitis or ocular syphilis. Woolston et al. \[[@B49]\] recently summarized the epidemiology and spectrum of the ocular findings of patients with ocular syphilis and supported the concept that ocular syphilis should be treated like neurosyphilis. Davis \[[@B50]\] described the clinical features of ocular syphilis, including some relatively unique signs of syphilitic uveitis, such as preretinal opacities or acute syphilitic posterior placoid choroiditis. They stated that the "treatment for syphilitic uveitis always follows the treatment regimen used for neurosyphilis and requires an examination of the cerebrospinal fluid." However, the outcomes of treatments were not analyzed in either review. Amaratunge et al. \[[@B55]\] reviewed cases of syphilitic uveitis reported between 1984 and 2008 in 41 articles and identified 143 patients with syphilitic uveitis, of which 65.0% had HIV coinfection. They reported that posterior uveitis was the most common phenotype (55.2%) and CSF abnormalities were more common in HIV-positive patients (76%); however, their results are not consistent with our results.

The good overall prognosis reported in prior studies suggests that further clinical trials of syphilitic uveitis are not urgently required. However, further studies may be valuable to establish the indications for corticosteroids or immunosuppressants. In addition, factors associated with final visual acuity and factors associated with HIV coinfection still needed to be investigated in suitably large studies. Because the global incidence of syphilitic uveitis is low, multicenter studies may be appropriate. Furthermore, understanding the pathogenesis of syphilis is compromised because *Treponema pallidum* is an exclusively human pathogen that cannot be grown in vitro. Moreover, very few studies have performed culture or polymerase chain reaction assays of intraocular fluid from patients with syphilitic uveitis \[[@B56]\]. In addition, some phenotypes of syphilitic uveitis were rare. For example, necrotizing retinitis was only reported in five studies included in our analysis, but it could be confused with acute retinal necrosis caused by herpes viruses. The analysis of aqueous humor in patients with necrotizing retinitis might be valuable in the differential diagnosis and to investigate the pathogenesis of this phenotype. Thus, future studies using aqueous humor samples from eyes with syphilitic uveitis may provide unique insight into direct spirochete infection and the consequent immune reactions. Such information might facilitate individualized treatment of syphilitic uveitis in patients with poor visual prognosis based on the current recommended therapies.

5. Conclusions {#sec5}
==============

Our systematic review summarized the complex clinical features of syphilitic uveitis, and our meta-analysis of published studies supports the use of antibacterial agents for treating syphilitic uveitis, regardless of HIV coinfection. However, we found no additional benefit of coadministering systemic corticosteroids and immunosuppressants with antibacterial agents relative to antibacterial monotherapy.
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###### 

Study characteristics and patient demographics.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                 Study design    Study period          Geographical location   Number of patients   Number of eyes   Number of dropouts or loss of follow-up   Age (years), range                             Males (%)   Ethnicity (%)
  --------------------- --------------- --------------------- ----------------------- -------------------- ---------------- ----------------------------------------- ---------------------------------------------- ----------- -----------------------------------------------------------
  Bollemeijier (2016)   Retrospective   1984--2013            Netherlands             85                   139              10                                        47 (27--73)                                    82.4        Caucasian (78.8), Surinam black (8.2),\
                                                                                                                                                                                                                                 African American (2.3), Asian (8.2), Surinam Indian (2.3)

  Dai (2016)            Retrospective   2011-2012             China                   25                   41               Unknown                                   53 (33--70)                                    72          Chinese (100.0)

  Fonollosa (2016)      Retrospective   2000--2012            Spain                   50                   93               0                                         41 (19--76)                                    61          ---

  Sahin (2016)          Retrospective   2012--2014            Turkey                  12                   17               0                                         43.75 (8--67)                                  58.3        Caucasian (100.0)

  Tsuboi (2016)         Retrospective   1997--2015            Japan                   20                   30               4                                         41 (32.5--46.5)                                100         Japanese (100.0)

  Zhang (2016)          Retrospective   2012--2015            China                   15                   26               0                                         50 (35--68)                                    60          Chinese (100.0)

  Lee (2015)            Retrospective   2008--2014            USA                     16                   29               2                                         48.5 (20--63)                                  100         Black (25.0), Hispanic\
                                                                                                                                                                                                                                 (56.2), white (12.5), others (6.2)

  Moradi (2015)         Retrospective   1984--2014            USA                     35                   61               4                                         45 (24--80)                                    74.3        African American (60.0),\
                                                                                                                                                                                                                                 Caucasian (40.0)

  Northey (2015)        Retrospective   2007--2012            Australia               25                   37               50% lost after 3 months                   41 (24--81)                                    92          ---

  Shen (2015)           Retrospective   2009--2014            China                   13                   21               4                                         50.3 ± 5.9 (37--61)                            53.8        Chinese (100.0)

  Mathew (2014)         Prospective     2009--2011            UK                      41                   63               0                                         47.5 (20.6--75.1)                              90.2        Caucasian (90.2), Afro\
                                                                                                                                                                                                                                 Caribbean (7.1); Arab (2.4)

  Rodrigues (2014)      Retrospective   2012 (Mar. to Oct.)   Brazil                  12                   19               Unknown                                   38.5 (28--55)                                  91.6        ---

  Yap (2014)            Retrospective   2004--2009            Singapore               12                   18               2 only at 1 month                         49.5 (24--84)                                  91.7        Chinese (75.0), Malays\
                                                                                                                                                                                                                                 (16.7), Indian (8.3)

  Restivo (2013)        Retrospective   2004--2010            Italy                   14                   21               0                                         46.2 ± 10.4 (26--66)                           92.9        ---

  Eandi (2012)          Retrospective   ---                   USA, Europe             16                   25               Unknown                                   40 (28--57)                                    87.5        Non-Latino white (93.8),\
                                                                                                                                                                                                                                 black (6.3)

  Yang (2012)           Retrospective   2004--2011            China                   19                   35               0                                         41.8 (19--70)                                  57.9        Asian (100.0)

  Balaskas (2011)       Retrospective   1999--2009            Switzerland             26                   42               3                                         45 (33--80)                                    69.2        Caucasian (80.8), African\
                                                                                                                                                                                                                                 (15.4), Asian (3.8)

  Li (2011)             Retrospective   1991--2009            USA                     13                   24               1                                         40 (30--67)                                    100         ---

  Hughes (2010)         Retrospective   2006--2009            Australia               13                   19               0                                         41.7 (29--29)                                  92.3        ---

  Li (2010)             Retrospective   92% after 2000        Not mentioned           13                   22               2-3 probably lost                         38 (26--55)                                    100         ---

  Kunkel (2009)         Retrospective   1998--2006            Germany                 24                   41               11                                        42.4 ± 2.5 (*n* = 13); 41.6 ± 3.0 (*n* = 11)   91.7        ---

  Fonollosa (2009)      Retrospective   2005--2007            Spain                   12                   18               0                                         47 (26--76)                                    83.3        ---

  Anshu (2008)          Retrospective   1995--2006            Singapore               22                   29               Unknown                                   52.7 (18--78)                                  77.3        ---

  Hong (2007)           Retrospective   1992--2004            Taiwan                  8                    14               0                                         57.7 (32--82)                                  87.5        ---

  Parc (2007)           Retrospective   2001--2004            France                  10                   11               6/10 lost after 3 months                  41.2 ± 9.9 (28--59)                            100         ---

  Tran (2005)           Retrospective   2001--2003            France                  12                   20               3                                         40 (28--56)                                    100         ---

  Shalaby (1997)        Retrospective   1983--1995            USA                     13                   23               5                                         37 (?--?)                                      92.3        ---

  Ormerod (2001)        Retrospective   1990--1993            USA                     21                   40               2                                         51 (29--72)                                    61.9        Black (76.2), no data (23.8)

  Browning (2000)       Retrospective   1986--1999            USA                     14                   24               0                                         42 (28--69)                                    71.4        African American (78.6), Caucasian (21.4)

  Villanueva (2000)     Retrospective   1993--1996            USA                     20                   Not mentioned    6                                         58 ± 14 (29--70)                               40          Black (100.0)

  Deschenes (1992)      Retrospective   1986--1990            Canada                  14                   24               Unknown                                   Mean: 50 for men, 63 for women                 64.3        ---

  Tamesis (1990)        Retrospective   1983--1989            USA                     25                   36               Unknown                                   Mean: 47 for men, 57 for women                 40          ---
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

UK: United Kingdom; USA: United States of America.

###### 

Clinical characteristics of patients with syphilitic uveitis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                 Bilaterality (%)   AU (%)   IU (%)   PU (%)   PAU (%)   ASPPC (%)   Retinitis, retinal\          Papillitis,\     HIV-positive (%)   CSF VDRL\
                                                                                            vasculitis, neuroretinitis   optic neuritis                      positive (%)
  --------------------- ------------------ -------- -------- -------- --------- ----------- ---------------------------- ---------------- ------------------ --------------
  Bollemeijier (2016)   63.5               15.8     1.4      30.2     47.5      ---         86.0                         74.0             35.9               38.7

  Dai (2016)            20.0               ---      ---      ---      ---       ---         22.0                         14.6             0.0                36.0

  Fonollosa (2016)      86.0               14.0     0.0      52.0     34.0      8.6         23.7                         33.3             34.0               15.0

  Sahin (2016)          41.7               29.4     11.8     29.4     11.8      ---         ---                          5.9              0.0                ---

  Tsuboi (2016)         50.0               10.0     6.7      50.0     20.0      6.7         ---                          53.3             100.0              ---

  Zhang (2016)          73.3               ---      ---      ---      ---       3.0         17.0                         9.0              13.3               ---

  Lee (2015)            81.3               13.8     ---      27.6     44.8      ---         ---                          13.8             62.5               20.0

  Moradi (2015)         74.3               36.1     23.0     8.2      45.9      3.3         ---                          ---              54.3               47.1

  Northey (2015)        52.0               32.4     ---      67.6     2.7       2.7         27.0                         27.0             32.0               42.9

  Shen (2015)           61.5               4.8      ---      ---      9.5       ---         52.4                         14.3             7.7                ---

  Mathew (2014)         56.0               9.5      1.6      12.7     41.3      ---         ---                          22.2             31.7               ---

  Rodrigues (2014)      58.3               5.3      ---      21.1     57.9      ---         5.3                          10.5             66.7               22.2

  Yap (2014)            50.0               33.3     5.6      27.8     33.3      ---         44.4                         33.3             25.0               44.4

  Restivo (2013)        50.0               ---      9.5      28.6     50.0      ---         ---                          ---              42.9               42.9

  Eandi (2012)                                                                                                                                               

  Yang (2012)           84.2               ---      ---      85.7     ---       5.7         94.3                         28.6             21.0               ---

  Balaskas (2011)       61.5               0.0      ---      50.0     45.2      ---         69.0                         31.0             7.7                5.5

  Hughes (2010)         46.2               10.5     10.5     36.8     47.4      ---         73.7                         ---              46.1               60.0

  Li (2010)             69.2               22.7     ---      23.1     30.8      ---         ---                          27.3             100.0              50.0

  Kunkel (2009)         71.0               17.1     ---      41.7     9.8       ---         ---                          26.8             45.8               29.1

  Fonollosa (2009)      50.0               ---      ---      5.6      94.4      ---         27.8                         27.8             75.0               75.0

  Anshu (2008)          31.8               75.9     10.3     13.8     27.6      3.4         27.6                         27.6             0.0                50.0

  Hong (2007)           75.0               ---      ---      7.1      78.6      ---         14.3                         28.6             0.0                20.0

  Parc (2007)           10.0               ---      ---      100.0    ---       ---         36.4                         72.7             80.0               22.2

  Tran (2005)           67.0               10.0     ---      ---      20.0      30.0        35.0                         25.0             100.0              ---

  Shalaby (1997)        83.0               30.8     23.1     ---      38.5      ---         ---                          7.7              100.0              63.6

  Li (2011)             85.0               ---      ---      41.7     58.3      ---         66.7                         41.7             83.0               25.0

  Ormerod (2001)        90.4               ---      ---      ---      5.0       2.0         17.5                         2.5              33.3               47.4

  Browning (2000)       71.4               ---      ---      ---      ---       ---         54.2                         12.5             36.0               22.2

  Villanueva (2000)     ---                ---      ---      ---      15.0      ---         10.0                         ---              33.3               20.0

  Deschenes (1992)      71.4               85.7     ---      \>0      \>0       ---         28.6                         14.3             66.7               ---

  Tamesis (1990)        44.4               29.4     5.9      17.6     47.1      ---         11.8                         17.6             8.0                50.0
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASPPC: acute syphilitic posterior placoid choroiditis; AU: anterior uveitis; CSF: cerebrospinal fluid; HIV: human immunodeficiency virus; IU: intermediate uveitis; PAU: panuveitis; PU: posterior uveitis; VDRL: venereal disease research laboratory test.

###### 

Clinical phenotypes of syphilitic uveitis.

  Phenotype                                       Number of studies (%)^∗^
  ----------------------------------------------- --------------------------
  Papillitis, optic neuritis, or neuroretinitis   28 (87.5)
  Panuveitis                                      24 (75.0)
  Retinitis, retinal vasculitis                   23 (71.9)
  Anterior uveitis                                21 (65.6)
  Posterior uveitis                               20 (62.5)
   ASPPC                                          10 (31.3)
   Choroiditis or chorioretinitis                 8 (25.0)
  Intermediate uveitis                            11 (34.4)
  Macular edema                                   7 (21.9)
  IOP increased                                   6 (18.8)
  Serous retinal detachment                       6 (18.8)
  Necrotizing retinitis                           5 (15.6)

ASPPC: acute syphilitic posterior placoid choroiditis; IOP: intraocular pressure; ^∗^number of studies that included patients with the specified clinical phenotype (of 32 studies included in this review).

###### 

Treatments and outcomes.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                 Intervention                                  Mean follow-up\                         Outcome                                                             
                                                                      time (months)                                                                                               
  --------------------- --------------------------------------------- --------------------------------------- --------- -------------------------- ------------------------------ -------
  Bollemeijier (2016)   Benzyl PNC 0.15 MU/kg/d IV (14 d),\           ±systemic, ±topical, ±subconjunctival   ---       6                          Improvement in visual\         91.5
                        or procaine PNC 1.2--2.4 MU IV (10--17 d),\                                                                                acuity, factors associated\    
                        or doxycycline 200 mg po bid (28 d),\                                                                                      with final visual acuity       
                        or ceftriaxone IV 2 g/d (14 d)                                                                                                                            

  Dai (2016)            ---                                           ---                                     ---       ---                        ---                            ---

  Fonollosa (2016)      74%: penicillin IV or IM, or combined.\       ---                                     ---       14                         Improvement in visual\         90.0
                        Others: oral doxycycline and\                                                                                              acuity, ocular complications   
                        ceftriaxone either IM or IV                                                                                                                               

  Sahin (2016)          PCN 24 MU/day IV (10 d)                       ±systemic                               ±         \>6                        Improvement in visual\         100.0
                                                                                                                                                   acuity and inflammation        

  Tsuboi (2016)         75% benzyl PNC 24 MU/d IV, amoxicillin\       ±systemic                               ---       21                         Improvement in visual\         100.0
                        po plus probenecid before or after                                                                                         acuity and inflammation        

  Zhang (2016)          All PNC G 18--24 MU/d IV (2 w),\              ---                                     ---       10.1                       Improvement in visual\         88.0
                        or ceftriaxone 2 g/d IV (2 w)                                                                                              acuity and inflammation        

  Lee (2015)            Benzyl PNC 18--24 MU/d IV (1014 d),\          ---                                     ---       1--96                      Improvement in\                100.0
                        or IV ceftriaxone (14 d), doxycycline\                                                                                     visual acuity                  
                        po (21 d)                                                                                                                                                 

  Moradi (2015)         PNC IV/IM, or ceftriaxion                     ±systemic                               ±         9                          Incidence of visual loss,\     52.0
                                                                                                                                                   ocular complications           

  Northey (2015)        Benzyl PNC IV (14 d), benzathine\             ±systemic, ±topical                     ---       6                          Improvement in visual\         87.0
                        PNC IM, doxycycline po                                                                                                     acuity and inflammation        

  Shen (2015)           Benzathine IM or ceftriaxone\                 ---                                     ---       4.1                        Improvement in\                92.3
                        IV or doxycycline po                                                                                                       visual acuity                  

  Mathew (2014)         ---                                           ---                                     ---       \>6                        Improvement in\                93.7
                                                                                                                                                   visual acuity                  

  Rodrigues (2014)      Crystalline PNC 20 MU/d IV (14 d)             ±systemic                               ---       ---                        Improvement in\                89.5
                                                                                                                                                   visual acuity                  

  Yap (2014)            PNC IV (10--14 d), or procaine PNC\           ±systemic, ±topical                     ---       \>3 (10/12 pt.)            Improvement in visual\         100.0
                        IM (10 d) + benzathine PNC G IM,\                                                                                          acuity and inflammation        
                        or benzathine penicillin G IM                                                                                                                             

  Restivo (2013)        PNC 24 MU/d (14 d)                            Topical                                 ---       29.4                       Improvement in visual\         71.4
                                                                                                                                                   acuity and inflammation        

  Eandi (2012)          PNC 24 MU/d (14 d)                            Systemic                                ---       2.9                        Improvement in visual\         100.0
                                                                                                                                                   acuity and inflammation        

  Yang (2012)           PNC 18--24 MU/d IV (14--20 d),\               Systemic (taper)                        ---       9.3                        Improvement in visual\         94.3
                        or doxycycline po                                                                                                          acuity and inflammation        

  Balaskas (2011)       PNC IV, or ceftriaxone                        ±systemic                               ±         10                         Improvement in\                84.2
                                                                                                                                                   visual acuity                  

  Hughes (2010)         PNC IV (10--14 d)                             ±systemic                               ---       ---                        Improvement in visual\         100.0
                                                                                                                                                   acuity and inflammation        

  Li (2010)             PNC IV (2 w) + PNC G benzathine\              ±systemic (taper)                       ---       ---                        Improvement in\                100.0
                        IM (1--3 w), or doxycycline po (4 w)                                                                                       visual acuity                  

  Kunkel (2009)         PNC G IV or ceftriaxone (≥10 d)               ---                                     ---       ---                        Improvement in\                61.5
                                                                                                                                                   visual acuity                  

  Fonollosa (2009)      PNC G IV 24 MU/d (14 d)                       ±intravitreal                           ---       19.8                       Improvement in\                100.0
                                                                                                                                                   visual acuity                  

  Anshu (2008)          Crystalline PNC G (18--24 MU/d)\              ±systemic, ±topical                     ---       ---                        Improvement in\                82.8
                        or procaine\                                                                                                               visual acuity                  
                        PNC (2--4 MU/d IM) with probenecid\                                                                                                                       
                        (10--14 d), or ceftriazone 2 g/d (10--14 d)                                                                                                               

  Hong (2007)           Crystal PNC G 12--18 MU/d\                    ±systemic prior\                        ---       4.3                        Improvement in visual\         100.0
                        (6--14 d) + PNC G 2.4\                        to diagnosis                                                                 acuity and inflammation        
                        MU/w IM (3-4 w), or PNC IV (10--14 d),\                                                                                                                   
                        or tetracycline 500 mg po qd (26 d)                                                                                                                       

  Parc (2007)           PNC G IV, or cetriaxone IV, or\               ---                                     ---       \>1 (all pt.); 5 (4 pt.)   Improvement in visual\         100.0
                        benzathine-benzyl PNC IM                                                                                                   acuity and inflammation        

  Tran (2005)           PNC 24 MU/day IV (≥14 d), or\                 ---                                     ---       7                          Improvement in visual\         100.0
                        ceftriaxone 2 g/day IV (21 d)                                                                                              acuity and inflammation        

  Shalaby (1997)        PNC 12--24 MU/d IV (10--14 d),\               Topical                                 ---       \>3 (8/13 pt.)             Improvement in visual\         100.0
                        or ceftriaxone 2 g/d IV (10 d)                                                                                             acuity and inflammation        

  Li (2011)             PNC IV (≥10 d), or PNC IM,\                   ---                                     ---       31                         Improvement in visual\         90.9
                        or ceftriaxone\                                                                                                            acuity and inflammation        
                        IM + PCN IV bolus, or tetracycline po                                                                                                                     

  Ormerod (2001)        Benzyl PNC IV (10--14 d), or a\               ---                                     ---       5                          Improvement in visual\         88.9
                        combination of PNC IV + benzathine\                                                                                        acuity and inflammation        
                        PNC IM,\                                                                                                                                                  
                        or benzathine PNC IM alone                                                                                                                                

  Browning (2000)       PNC IV (10 d), or benzathine\                 ---                                     ---       6                          Improvement in visual\         83.3
                        PNC IM + probenecid po                                                                                                     acuity and inflammation        

  Villanueva (2000)     Crystalline PNC G 12--24 MU/d IV              ±topical                                ---       12.9                       Improvement in\                ---
                                                                                                                                                   ocular lesions                 

  Deschenes (1992)      PNC 18--24 MU/d IV (10--14 d) + PNC\          ---                                     ---       ---                        Improvement in\                78.9
                        2.4 MU/w IM, or PNC IM (2-3 w),\                                                                                           visual acuity                  
                        or tetracycline                                                                                                                                           

  Tamesis (1990)        PNC, no details                               ±topical                                ---       10                         Improvement in visual\         100.0
                                                                                                                                                   acuity and inflammation        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASPPC: acute syphilitic posterior placoid choroiditis; bid: twice daily; CSF: cerebrospinal fluid; d: days; IM: intramuscular; IV: intravenous; MU: million unit; PNC: penicillin; po: per os (oral).

###### 

Ocular complications and systemic adverse events (318 eyes).

  -------------------------------------------------------------------
  Complications                  Number of events\   *N*/*N*^a^ (%)
                                 (proportion, %)     
  ------------------------------ ------------------- ----------------
  Ocular complications                               

   Cataract                      41 (29.5)           12.9

   Ocular HTN                    15 (10.8)           4.7

   PS                            15 (10.8)           4.7

   Chorioretinal scarring        12 (8.6)            3.8

   ERM                           12 (8.6)            3.8

   ME                            10 (7.2)            3.1

   Optic disc atrophy            10 (7.2)            3.1

   RD                            8 (5.8)             2.5

   PVR                           5 (3.6)             1.6

   Phthisis bulbi                4 (2.9)             1.3

   Others                        7 (5.0)             2.2

   Total                         139 (100)           43.7

  Systemic adverse events                            

   Jarisch-Herxheimer reaction   3                   2.2 (of 136\
                                                     patients)
  -------------------------------------------------------------------

ERM: epiretinal membrane; HTN: hypertension; ME: macular edema; PS: posterior synechiae; PVR: proliferative vitreoretinopathy; RD: retinal detachment; ^a^percentage of eyes with ocular complications in a total of 318 eyes included in eight studies that reported complications.

###### 

Subgroup analysis of efficacy of antibacterial monotherapy of syphilitic uveitis.

  Subgroup                      Number of studies   Pooled success rate (95% CI)   *I* ^2^ (%)   *P* ~heterogeneity~
  ----------------------------- ------------------- ------------------------------ ------------- ---------------------
  Publication year                                                                               
   \>2009                       6                   0.86 (0.71--0.97)              82.4          \<0.0001
   ≤2009                        9                   0.94 (0.85--1.00)              70.6          0.0007
  Number of eyes                                                                                 
   \<25                         9                   0.93 (0.85--0.99)              57.9          0.0149
   ≥25                          6                   0.88 (0.72--0.98)              87.7          \<0.0001
  Geographical location                                                                          
   North America                7                   0.88 (0.74--0.98)              81.5          \<0.0001
   Europe                       6                   0.92 (0.79--0.99)              75.7          0.0010
   China                        2                   0.98 (0.85--1.00)              48.2          0.1648
  HIV positivity (%)                                                                             
   ≥50                          7                   0.93 (0.78--1.00)              81.3          \<0.0001
   \<50                         8                   0.90 (0.80--0.97)              74.6          0.0003
  Follow-up duration (months)                                                                    
   ≥12                          4                   0.90 (0.79--0.98)              64.9          0.0151
   \<12                         7                   0.97 (0.91--1.00)              55.8          0.0348
   Unclear                      4                   0.76 (0.50--0.95)              78.9          0.0026

CI: confidence interval; HIV: human immunodeficiency virus.

[^1]: Academic Editor: Suphi Taneri
